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Hypertension
CLINICAL STATEMENTS AND GUIDELINES

Hypertension Pharmacological Treatment in
Adults: A World Health Organization Guideline
Executive Summary
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Hind Mamoun Beheiry, Beatriz Champagne, Kenneth Connell , Marie Therese Cooney, Nnenna Ezeigwe,
Thomas Andrew Gaziano , Agaba Gidio, Patricio Lopez-Jaramillo, Unab I. Khan, Vindya Kumarapeli , Andrew E. Moran,
Margaret Mswema Silwimba, Brian Rayner , Apichard Sukonthasan, Jing Yu, Nizal Saraffzadegan, K. Srinath Reddy,
Taskeen Khan
ABSTRACT: Hypertension is a major cause of cardiovascular disease and deaths worldwide especially in low- and middle-income
countries. Despite the availability of safe, well-tolerated, and cost-effective blood pressure (BP)-lowering therapies, <14% of adults
with hypertension have BP controlled to a systolic/diastolic BP <140/90 mm Hg. We report new hypertension treatment guidelines,
developed in accordance with the World Health Organization Handbook for Guideline Development. Overviews of reviews of the
evidence were conducted and summary tables were developed according to the Grading of Recommendations, Assessment,
Development, and Evaluations approach. In these guidelines, the World Health Organization provides the most current and relevant
evidence-based guidance for the pharmacological treatment of nonpregnant adults with hypertension. The recommendations
pertain to adults with an accurate diagnosis of hypertension who have already received lifestyle modification counseling. The
guidelines recommend BP threshold to initiate pharmacological therapy, BP treatment targets, intervals for follow-up visits, and
best use of health care workers in the management of hypertension. The guidelines provide guidance for choice of monotherapy
or dual therapy, treatment with single pill combination medications, and use of treatment algorithms for hypertension management.
Strength of the recommendations was guided by the quality of the underlying evidence; the tradeoffs between desirable and
undesirable effects; patient’s values, resource considerations and cost-effectiveness; health equity; acceptability, and feasibility
consideration of different treatment options. The goal of the guideline is to facilitate standard approaches to pharmacological
treatment and management of hypertension which, if widely implemented, will increase the hypertension control rate world-wide.
Key Words: blood pressure ◼ cardiovascular disease ◼ hypertension ◼ pharmacotherapy

C

ardiovascular disease (CVD) is the leading cause
of death worldwide, with most deaths attributed to
hypertension resulting from coronary heart disease
or stroke and more than three quarters of these deaths
occurring in low- and middle-income countries.1 The
level of high blood pressure (BP) is directly related to
many adverse outcomes, including CVD and kidney disease.2 Conversely, clinical trials have repeatedly demonstrated that lowering BP in adults with high baseline
BP level provides an effective means for preventing
CVD. Definitions of hypertension are useful for clinical

decision-making and are typically based on CVD risk
and level of BP at which antihypertensive medication is
effective for preventing CVD.3 A common definition of
hypertension is based on an average systolic BP (SBP)
≥140 mm Hg, diastolic BP (DBP) ≥90 mm Hg, or selfreported use of antihypertensive medication. Using
this definition, it has been estimated that ≈1.4 billion
adults have hypertension, worldwide, but <14% have
their BP controlled with antihypertensive drug therapy
to an SBP/DBP <140/90 mm Hg (<8% in low- and
middle-income countries).3 Even more disturbing is

Correspondence to: Akram Al-Makki, Indiana University Health Arnett. Email almakkia@iuhealth.org
For Sources of Funding and Disclosures, see page 301.
© 2021 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article
under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is
properly cited.
Hypertension is available at www.ahajournals.org/journal/hyp

Hypertension. 2022;79:293–301. DOI: 10.1161/HYPERTENSIONAHA.121.18192

January 2022   293

ClinicalStatementsandGuidelines

Al-Makki et al

WHO Guidelines on Treatment of HTN in Adults

Nonstandard Abbreviations and Acronyms
BP
blood pressure
CKD
chronic kidney disease
CVD
cardiovascular disease
DBP
diastolic BP
GDG
Guideline Development Group
GRADE	Grading of recommendations, Assessment, Development and Evaluation
SBP
systolic BP
WHO
World Health Organization

the recent trend in a high-income country (the United
States), where rate of hypertension control to an SBP/
DBP <140/90 mm Hg reached a high of close to 54%
in 2013 to 2014, but dramatically eroded to <44% in
2017 to 2018.4 Given this decrease, the Surgeon General of the United States issued a report for a “Call to
Action to Control Hypertension” making the control of
hypertension a national priority.5
In 1978, the World Health Organization (WHO) published one of the earliest clinical practice guidelines for
the diagnosis and management of arterial hypertension, which were later updated in 1999 and 2003.6,7 In
2007, the WHO published some recommendations for
the management of hypertension in guidelines for the
assessment and management of total CVD risk. However, these are now outdated considering new evidence
and practices.8 Guidance is particularly needed now on
some controversial issues, such as the threshold level
of BP at which to start pharmacological treatment and
whether laboratory testing and CVD risk assessment are
needed before initiating antihypertensive pharmacological therapy. In the past decade, the WHO included diagnosis and management of hypertension in a total CVD
risk approach as part of the WHO Package of Essential Noncommunicable Disease Interventions (WHO
PEN) 2007, 2010, and 2013.9 However, this approach
preceded recent advances in the pharmacological management of hypertension. More recently, the WHO has
provided information about the diagnosis and management of hypertension in the Global HEARTS Initiative including the HEARTS Technical Package and the
HEARTS in the Americas Program.10,11 However, these
too provide general practical information and not specific
guidelines and recommendations. The WHO Essential
Medicines List includes ACE (angiotensin-converting
enzyme) inhibitors, calcium channel blockers, angiotensin
receptor blockers, and thiazide diuretics for management
of hypertension. In June 2019, single-pill combination
antihypertensive medications were added to the WHO
Essential Medicines List.12
Herein, we summarize the recommendations of
the 2021 WHO Guidelines for the Pharmacological
294   January 2022

Treatment of Hypertension in Adults. They include
guidance on the BP threshold for the initiation of pharmacological treatment for hypertension, initial and longer-term visit intervals for follow-up of treated patients,
treatment target BP levels, and the best use of health
care workers for management of hypertension. The
2021 WHO hypertension guidelines aim to provide the
most current and relevant evidence-based guidance
for pharmacological treatment of hypertension in nonpregnant adults, with a particular focus on practice in
middle- and low-income countries.
Although these guidelines do not address modifiable risk factors for hypertension such as unhealthy
diet, overweight, obesity, physical inactivity, or consumption of alcohol, a comprehensive treatment plan
for hypertension should address these risk factors
through lifestyle modifications and other interventions.3 Likewise, treatment of hypertension should be
accompanied by management of other CVD risk factors such as cigarette smoking, diabetes, lipid abnormalities, and comorbid conditions.13
The 2021 WHO hypertension guidelines are
focused on management in routine, primary care settings (primary care health care providers, family physicians, cardiologists, nephrologists, and any providers
who manage hypertension) and do not address the
treatment of hypertensive emergencies or urgencies, secondary forms of hypertension, or resistant
hypertension.

MATERIALS AND METHODS
Guideline Contributors
To develop the hypertension guidelines, the WHO established
4 groups:
1. An internal WHO Steering Group to coordinate the guideline development process.
2. A Guideline Development Group (GDG), composed of a
diverse group of primary care and subspecialty physicians
who were hypertension experts, pharmacists, nurses,
health-oriented academics, a patient representative, and
policymakers to review the evidence and develop recommendations. The WHO selected the members of the GDG
based on relevant expertise but also considered appropriate representation by region and sex. An independent
methodologist facilitated GDG deliberations.
3. An External Review Group, composed of technical
experts, representatives of hypertension patient groups,
and ministries of health from low-resource countries, to
provide peer review of the guidelines.
4. An independent contracted systematic review group
that conducted the overview of reviews and summarized
evidence.
The guidelines were developed in accordance with the
WHO Handbook for Guideline Development. In brief, the WHO
Steering Group, in collaboration with the Guideline Development
Group, developed key questions and rated outcomes to identify
those critical for the development of the guidelines. Conflicts of
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Guideline Scope and Questions
Members of the WHO GDG developed an analytic framework that linked hypertension treatment to important health
outcomes (Figure 1) in which 11 clinical questions were prioritized. The framework linked pharmacological treatments
of hypertension to intermediate health outcomes and final
health outcomes, as well as adverse events of testing. The
GDG rated each outcome on a scale from 1 to 9 and indicated whether it considered each outcome critical (rated
7–9), important (rated 4–6) or not important (rated 1–3),
for decision-making.

Reviews of Evidence
The systematic review group conducted systematic searches of
the literature to identify existing systematic reviews published
between 2015 and 2020 in PubMed, Embase, The Cochrane
Library, and Epistemonikos that addressed the 11 questions.
When multiple reviews were published, systematic reviews were
prioritized to inform the recommendations based on quality
(assessed by the Methodological Quality of Systematic Reviews,
AMSTAR); how well they addressed the questions; whether they
reported sufficient information to assess the quality of the evidence; whether they reported evidence for subgroups of interest (eg, patients with diabetes, CVD, chronic kidney disease
[CKD], etc); and the date of the most recent search. Content
experts were queried for additional literature. The reviews published since 2015 include the major studies that were published before 2015 and the more recently published landmark
studies. We have carefully reviewed the studies that informed
recent guidelines, and we reference them in the detailed guideline report. In addition to our primary search of the literature, we
cross referenced existing systematic reviews and guidelines to
identify any additional studies. All this information is detailed in
the full guideline document and the Supplemental Material.
A total of 159 systematic reviews and 17 additional primary studies were identified, including 9 individual patient data

Figure 1. Analytic framework for management of hypertension.
BP indicates blood pressure; CAD, coronary artery disease; CV, cardiovascular; ESRD, end-stage renal disease; HTN, hypertension; KQ, key
question, and MI, myocardial infarction.
Hypertension. 2022;79:293–301. DOI: 10.1161/HYPERTENSIONAHA.121.18192
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interest were handled in line with the current Compliance, Risk
Management and Ethics policy and all members of the GDG
were asked to fill in the standard WHO Declaration of Interest
forms, which were reviewed. An overview of systematic reviews
of the evidence were used to build summary of findings tables
according to the Grading of recommendations, Assessment,
Development and Evaluations (GRADE) approach. The
Guideline Development Group developed recommendations,
considering the certainty of the evidence, the balance between
desirable and undesirable effects, resource requirements and
cost-effectiveness, health equity, acceptability, patient values
and preferences, and feasibility.
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analyses. An additional overview of systematic reviews was
used to inform other decision criteria in the evidence-to-decision framework, including patient’s values, resources, acceptability, feasibility, and equity. No direct evidence was identified
for the question about obtaining laboratory testing. Therefore,
a conceptual model was used to derive indirect evidence that
could help to answer the question (Figure 2). The model linked
testing to final health outcomes by describing the desirable and
undesirable effects of testing. Indirect evidence incorporated in
this model provided a rationale for testing and facilitated GDG
recommendations.

Certainty of Evidence and Strength of
Recommendations
The GDG rated the certainty of evidence and developed the
recommendations using the GRADE approach.14 When making recommendations, GRADE defines the quality of a body of
evidence as “the extent of our confidence that the estimates of
an effect are adequate to support a particular decision or recommendation”.15 The strength of the recommendations reflects
the degree of confidence of the GDG that the desirable effects
(eg, beneficial health outcomes) of the recommendations outweigh the undesirable effects (eg, adverse effects). According
to the GRADE approach, the certainty of the evidence can be
high, moderate, low, or very low (Table). The recommendations
were graded into 2 categories:
1. A strong recommendation represented GDG confidence
that the desirable effects of adhering to the recommen-

dation outweighed undesirable effects.
2. A weak or conditional recommendation represented a
GDG conclusion that the desirable effects of adhering to

the recommendation probably outweighed the undesirable effects.

Deciding Upon Recommendations
The GDG initially met in person in July 2019 where they
reviewed a scoping document and developed the specific
Population, Intervention, Comparison, and Outcome questions
to be addressed in the guidelines. Subsequently and because
of the coronavirus disease 2019 (COVID-19) pandemic, the
GDG met virtually for 4 sessions in February 2021. Systematic
reviews and GRADE tables were discussed at the meeting.
Formulation of recommendations and their strength were facilitated by the GDG chair and supported by the methodologist,
with the aim of achieving unanimous consensus. While the plan
was to use a simple majority vote, full consensus was reached
on all recommendations.

RESULTS/RECOMMENDATIONS
The 11 questions led to 8 recommendations that are
summarized in Figure 3. GDG judgments on certainty
of evidence, each decisional factor, contextual information, and balance of desirable and undesirable effects
are available in the full WHO guideline. Each recommendation was accompanied by implementation remarks
and considerations to facilitate adaptation and application by various countries and systems. The External
Review Group provided peer review of the guidelines
and ensured recommendations are aligned with current global needs. Evidence informing each of the

Figure 2. Conceptual model used to derive indirect evidence that helped to answer the question about laboratory testing.
CKD indicates chronic kidney disease; DM, diabetes; HTN, hypertension; LVH, left ventricular hypertrophy; and PICO, population, intervention,
comparison, and outcome.
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Quality of
Evidence

Definition

High

We are very confident that the true effect lies close to that of
the estimate of effect.

Moderate

We are moderately confident in the effect estimate. (The true
effect is likely to be close to the estimate of effect, but there
is a possibility that it is substantially different.)

Low

Our confidence in the effect estimate is limited. (The true effect
may be substantially different from the estimate of the effect.)

Very low

We have very little confidence in the effect estimate. (The
true effect is likely to be substantially different from the
estimate of effect.)

recommendations, certainty of evidence, patients’ values,
resources, feasibility, acceptability, and equity considerations can be accessed in the WHO’s full document that
is available online (https://apps.who.int/iris/bitstream/
handle/10665/344424/9789240033986-eng.pdf).

DISCUSSION
The prevalence, treatment, and control of hypertension
vary substantially between different countries with the
greatest burden of disease due to hypertension and
the lowest proportions of treated and controlled hypertension being in low- and middle-income countries.16
Hypertension has been repeatedly demonstrated as the
most important single modifiable risk factor responsible
for CVD burden of disease and all-cause mortality and
hypertension is a significant global public health issue
by the WHO.17 The global burden of hypertension has
been growing over time, driven by changes in lifestyle,
population growth, inadequate treatment, and aging.
Long-term sequelae of untreated/uncontrolled hypertension include increased CVD events, end organ damage, and mortality.18,19 High BP is also closely related
to other adverse outcomes including CKD and cognitive impairment/dementia.2,20 A wide array of effective
hypertension treatment options exists, ranging from
lifestyle modifications to various forms of antihypertension medications. Alarmingly, SBP/DBP is controlled
to <140/90 mm Hg in <14% of adults worldwide and
<8% on low- and middle-income countries.16 In the
guidelines summarized in Figure 3, the WHO provides
the most current and relevant evidence-based guidance for the pharmacological treatment of nonpregnant
adults with hypertension. The recommendations pertain
to adults with an accurate diagnosis of hypertension
who have already received lifestyle counseling. The
guidelines provide recommendations for a BP threshold to initiate pharmacological therapy, BP treatment
targets, intervals for follow-up visits, and best use of
health care workers during treatment of hypertension.
The guidelines provide guidance for monotherapy,
dual therapy, treatment with single-pill combinations,
and the use of treatment algorithms for hypertension

management. The recommendations are guided by the
quality of the underlying evidence, the balance between
expected beneficial and undesirable effects, resource
requirements and cost-effectiveness, health equity,
acceptability, patient values and preferences, and feasibility of the treatment.
In the GDG recommended guidelines (Figure 3),
the evidence base for recommendation on target BP
consisted of systematic reviews as well as a review of
relevant trials.21–23 In patients with comorbidity (CAD,
DM, CKD), there is consistent benefit with lower targets (variable thresholds); however, data in these
subgroups were imprecise and the evidence was less
certain. Therefore, the GDG cautions against applying this evidence to lower-risk patients with raised BP
or hypertension. Adverse events such as dizziness in
intensive control group and ischemia in patients with
coronary artery disease can shift the balance of benefits and harms in older individuals (those aged 65 years
or older). Concern about lower adherence due to the
need for extra patient and provider effort to reach lower
targets should also be balanced against intensive control. The overall certainty of the evidence was judged to
be moderate, with large benefits and moderate harms.
The GDG made a judgement that the desirable effects
outweigh the undesirable effects at a treatment goal of
<140/90 mm Hg in all patients with hypertension without comorbidities and SBP <130 mm Hg in high-risk
patients with hypertension—those with high CVD risk,
diabetes, and CKD. More evidence is required about
treatment of those in the SBP 130 to 139 range who
fall into one or more of the following subgroups: diabetes, CKD, heart failure, 65 years or older.
CVD risk assessment strategy for those without existing CVD can be based on age, sex, body mass index, BP,
previous antihypertensive treatment, smoking, diabetes,
and history of CVD.24
Most patients with an average SBP ≥140 or DBP
≥90 mm Hg are at high risk for CVD and initiation of antihypertensive drug therapy is indicated. Although helpful,
cardiovascular (CVD) risk assessment is not mandatory
before initiating antihypertensive drug treatment. CVD
risk assessment is most important for guiding decisions
about initiating pharmacological treatment for hypertension in those with a lower average SBP (130–139
mm Hg). In all adults with hypertension, it is important
that other risk factors for CVD be identified and treated
appropriately to lower total cardiovascular risk. Many
CVD risk-assessment instruments are available. In the
absence of a calibrated equation for the local population,
the choice should depend on the resources available,
and the acceptability and feasibility of the available CVD
risk predicting tools. Whenever CVD risk assessment
may impede the timely initiation of hypertension treatment and/or patient follow-up, it should be postponed
and included as a follow-up strategy.

Hypertension. 2022;79:293–301. DOI: 10.1161/HYPERTENSIONAHA.121.18192
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Figure 3. Recommendations in the World Health Organization Guideline: Pharmacological Treatment of Hypertension in
Adults 2021.
CVD indicates cardiovascular disease; and WHO, World Health Organization.

Prevailing concepts about BP have changed dramatically over time. Results of the Framingham Heart Study and
many other cohort studies have shifted the emphasis from
298   January 2022

DBP to SBP by demonstrating that SBP was a more important predictor of CVD risk compared with DBP.25 In addition,
almost all the recent landmark clinical trials have employed
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be over-represented in vulnerable populations. Therefore, improvement of hypertension treatment and control
through better treatment and a lower BP target could
reduce long-standing inequality. The goal of the guideline
is to facilitate uptake of a standard approach to the pharmacological treatment and management of hypertension
which, in turn, will increase the hypertension control rate
world-wide. However, several research gaps were identified by the GDG according to the theme of the PICOs
(Figure 4). These gaps are summarized as follows:
1. Thresholds to determine initiation of therapy and
targets to achieve BP control: more evidence is
required about treatment of those in the baseline
SBP 130 to 139 mm Hg range who fall into one or
more of the following subgroups: DM, CKD, heart
failure, and older age. There is a need for better
outcomes data from trials that include dementia and cognitive impairment among outcomes.
Clinical significance of treatment-related adverse
events registered in clinical trials needs greater
clarity. There is a need to quantify the difference
in estimates between blinded, placebo-controlled
trials and unblinded, active control trials using a
standard framework. There is a need for period
analysis of trials to capture effects of changes over
time in background epidemiology of CVD, non-BP
treatments, competing risks, etc. More evidence is
needed from low-income countries, middle-income
countries, and important high-risk subpopulations

Figure 4. Research gaps identified
by Guideline Development Group
(GDG) according to population,
intervention, comparison, and
outcome.
BP indicates blood pressure; COVID-19,
coronavirus disease 2019; CVD,
cardiovascular disease; and HTN,
hypertension.
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SBP rather than DBP as an inclusion criterion and for the
trial BP treatment goals. Current US guidelines recommend
an intensive BP target of <130/80 mm Hg without mentioning the lower limits of diastolic BP.26 A recent cohort
study found that lowering diastolic BP to <60 mm Hg was
associated with increased risk of cardiovascular events
in patients with high cardiovascular risk and a treated
SBP <130 mm Hg. The finding that a diastolic BP value
between 70- and 80-mm Hg was an optimum target for
this patient population merits further study, the results in this
DBP group should be interpreted with caution, and these
results may not apply to the general population.27 Since
most recent clinical trials/studies use the SBP to initiate
treatment as well as a treatment goal therefore the GDG
felt it was appropriate to use SBP in the recommendation.
Intensive treatment for selected patients adds complexity for health workers; emphasis on team-based care
in low-resource settings means that simple, protocolized
care is needed. Intensive treatment for some patients
complicates treatment protocols and may lead to decisional overload, especially for health workers with more
limited training and/or autonomy. On the other hand, strict
BP targets in the general population with hypertension are
likely to be less acceptable to stakeholders. Most available evidence is derived from high-risk patients receiving intensive treatment and not the general population
living with hypertension. Treating BP will reduce health
inequity because preventing CV events reduces mortality
across the population. Uncontrolled hypertension might

WHO Guidelines on Treatment of HTN in Adults
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living in high-income countries. An assessment of
the feasibility, resource needs, and costs of intensive
BP treatment of high-risk hypertension patients in
real clinical practice is needed. The resource commitment required for more intensive treatment in
LMICs needs to be quantified. The opportunity cost
of directing resources toward achieving SBP <130
in high-risk individuals needs to be established.
Research is needed on the feasibility, acceptability,
and efficacy of intensive treatment, especially in
high-risk populations in low-income countries and
middle-income countries.
Laboratory tests to determine initiation of treatment: a greater understanding is required, of the
essential tests to be performed in all patients, to
reduce costs and improve outcomes.
Role of CVD risk in hypertension treatment: an
exploration is needed of key operational aspects
of the implementation of a risk-based approach to
CVD prevention and BP-lowering pharmacological
treatment in primary health care settings. Additional
validation of CVD risk estimating tools, which are
known to be population specific, is also needed.
Monotherapy versus combination therapy: a comparison is required of long-term data about hard
clinical end points between monotherapy and combination therapy. There is a need for research studies
on real-world experiences, designed and statistically powered, to determine if there is a difference
in clinical outcomes, such as reduction in MACE,
mortality, and serious adverse events between
single-pill combinations versus multiple-pill combinations. Health economic analyses are needed to
quantify cost-effectiveness and budget implications
of implementing incremental initial combination
therapy compared with initial monotherapy.
Frequency of reassessment: criteria establishing
the clinical definition of stable BP control will be
needed to guide the selection of patients requiring
less frequent follow-up visits. Research is needed
for early and accurate identification of patients less
likely to achieve BP control and less likely to follow up as requested by their health care provider.
Better evidence is needed on the timing, frequency,
and intensity of interventions that improve treatment adherence.
Team-based care for hypertension: evidence is
needed that remote monitoring and use of community HCWs/navigators can assist in the management of BP. Evidence of the feasibility, costs, and
effectiveness of community/home-based monitoring of BP is needed.
Hypertension in disaster, humanitarian, and emergency settings: assessment of hypertension and
appropriate resourcing to treat it should be a priority
for agencies providing emergency and longer-term
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care for patients after or during humanitarian crises to prevent significant mortality and morbidity.
Further studies are needed to accurately estimate
prevalence of hypertension in crisis-affected populations throughout the world and to evaluate the
best treatment approach for this population.
8. COVID-19 and hypertension: further research that
will address key unanswered questions about the
role of the RAAS in the pathogenesis and possible
treatment of COVID-19 and other coronavirusbased diseases is needed. Prospective studies—in
particular, randomized, placebo-controlled trials
may provide clearer insight about the effect of
ACE inhibitors or ARBs in patients with COVID-19.

CONCLUSIONS
In the above guidelines, the WHO provides the most current and relevant evidence-based global public health
guidance on the initiation of treatment with pharmacological agents for hypertension in adults. The guidelines are
expected to be valid for a period of 5 years. This period
reflects the fact that new research findings are likely to
become available in the meantime but also represents
a feasible time frame, considering the costs, time and
other resources that are needed to update such guidelines. If the evidence base or user needs change before
the 5-year mark, consideration will be given to producing
updates sooner. More large randomized controlled trials,
powered for CVD and/or mortality outcomes, are needed
to shed light on the research gaps mentioned in discussion above especially for subpopulations that have not
been adequately represented in previous trials.
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